Systematic Review and Meta-analysis

Direct Oral Anticoagulants vs Vitamin K Antagonists in Left Ventricular Thrombi: A Systematic Review and Meta-analysis

Faith Michael, MD, a,† Navneet Natt, MD, a,b,‡ and Mohammed Shurrab, MD, MS c,b,c,d

a Northern Ontario School of Medicine, Laurentian University, Sudbury, Ontario, Canada
b Cardiology Department, Health Sciences North, Sudbury, Ontario, Canada
c Health Sciences North Research Institute, Sudbury, Ontario, Canada
d Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada

ABSTRACT

Background: There is increasing interest in direct oral anticoagulants (DOACs), given their safety and convenience in atrial fibrillation, compared with vitamin K antagonists (VKAs). However, the use of DOACs in left ventricular (LV) thrombus formation is still under question, with current guidelines recommending VKAs. The aim of this meta-analysis was to compare the safety and efficacy of DOACs to VKAs in the management of LV thrombi.

Methods: A systematic search was conducted for studies published between January 1, 2009 and January 31, 2021 in PubMed, Embase, and CENTRAL. Included studies compared DOACs to VKAs for the treatment of LV thrombi and reported on relevant outcomes. Odds ratios (ORs) were pooled with a random-effects model.

Results: Sixteen cohort studies and 2 randomized controlled trials were identified, which included 2666 patients (DOAC = 674; VKA = 1992). Compared with VKAs, DOACs were associated with a statistically significant reduction in stroke (OR 0.63, 95% CI 0.41-1.44; P = 0.03), stroke or systemic embolism (OR 0.77, 95% CI 0.41-1.44; P = 0.41; I^2 = 0%), systemic embolism (OR 0.83, 95% CI 0.53-1.33; P = 0.45; I^2 = 33%), mortality (OR 1.01, 95% CI 0.64-1.57; P = 0.98; I^2 = 0%) or LV thrombus resolution (OR 1.29, 95% CI 0.83-1.99; P = 0.26; I^2 = 56%).

Left ventricular (LV) thrombus formation complicates 15% of acute myocardial infarctions (MIs), and it is even more common in conditions of impaired LV systolic function.1-5 If left untreated, up to 20% of patients can have significant complications, including stroke and systemic embolism.3 Current consensus guidelines recommend the use of vitamin K antagonists (VKAs) to treat LV thrombi following acute MIs for 3-6 months.4,5

Direct oral anticoagulants (DOACs) are a preferred alternative to VKAs, as they have lower bleeding rates, fewer drug interactions, rapid onset of action, and decreased need for monitoring.6 However, the use of DOACs for this indication remains off-label. Many observational studies have shown comparable safety and efficacy of DOACs to VKAs in the management of LV thrombi.7-9 However, a recent large cohort study identified a higher risk of stroke or systemic embolism with DOACs, calling into question their use in the treatment of LV thrombi.10

The aim of this systematic review and meta-analysis was to compare the safety and efficacy of DOACs to VKAs in the

RéSUMÉ

Introduction : Les anticoagulants oraux directs (AOD) font l’objet d’un intérêt grandissant par rapport aux antagonistes de la vitamine K (AVK) en raison de leur innocuité et de leurs avantages lors de fibrillation auriculaire. Toutefois, l’utilisation des AOD lors de thrombî du ventricule gauche (VG) est considérée comme non conforme selon les lignes directives actuelles qui recommandent les AVK. L’objectif de la présente méta-analyse était la comparaison de l’innocuité et de l’efficacité des AOD aux AVK dans la prise en charge des thrombi du VG.

Méthodes : Nous avons réalisé une recherche systématique pour trouver des études publiées entre le 1er janvier 2009 et le 31 janvier 2021 dans PubMed, Embase et CENTRAL. Les études sélectionnées qui portaient sur la comparaison des AOD aux AVK dans le traitement des thrombi du VG ont rendu compte de résultats pertinents. Nous avons regroupé les ratios d’incidence approché (RIA) au moyen d’un modèle à effets aléatoires.

Résultats : Nous avons relevé 16 études de cohorte et deux essais cliniques à répartition aléatoire auprès de 2 666 patients (AOD = 674; AVK = 1 992). Par rapport aux AVK, les AOD étaient associés à une réduction significative sur le plan statistique lors d’accidents vasculaires cérébraux (AVC) (RIA 0.63, intervalle de confiance [IC] à 95 % 0,42-0,96; P = 0,03; I^2 = 0 %). Il n’y avait aucune différence significative en ce qui concerne les hémorragies (RIA 0,72, IC à 95 % 0,50-1,02; P = 0,07; I^2 = 33 %), l’embolie systémique (RIA 0,77, IC à 95 % 0,41-1,44; P = 0,41; I^2 = 0 %), les AVC ou l’embolie systémique (RIA 0,83, IC à 95 % 0,53-1,33; P = 0,45; I^2 = 33 %), mortalité (RIA 1,01, IC de 95 % 0,64-1,57; P = 0,98; I^2 = 0 %) ou résolution thrombus LV (RIA 1,29, IC de 95 % 0,83-1,99; P = 0,26; I^2 = 56 %).
Conclusions: Within the context of low-quality evidence, there was a statistically significant reduction in stroke among those treated with DOACs, without an increase in bleeding. There were no significant differences in systemic embolism, stroke or systemic embolism, mortality, or LV thrombus resolution, suggesting that DOACs may be a reasonable option for treatment of LV thrombi.

management of LV thrombi. The primary outcomes of our review were stroke and bleeding, and secondary outcomes included systemic embolism (SE), stroke or systemic embolism (SSE), mortality, and LV thrombus resolution.

Methods

Literature search and data sources

A systematic search of the literature was conducted by 2 investigators (F.M., N.N.) in PubMed, Embase, and CENTRAL for studies published between January 1, 2009 and January 31, 2021. The PubMed search terms were: (DOAC OR NOAC OR anticoag* OR factor Xa inhibitor OR antithrombin OR rivaroxaban OR dabigatran OR apixaban OR edoxaban) AND [(left ventric* OR LV) AND (thromb* OR clot)]. The PubMed search strategy is available as Supplemental Appendix S1. Language restrictions were not applied. All studies obtained from the search were reviewed manually in duplicate (by F.M. and N.N.) for inclusion. We also searched for grey literature through databases (Scopus and OpenGrey), manual web searches, and conference proceedings, in addition to ClinicalTrials.gov for ongoing trials. The reference lists of relevant articles, including systematic reviews and meta-analyses, were hand searched.

Study selection and quality assessment

The following inclusion criteria were applied: (i) studies must compare DOACs to VKAs in the management of LV thrombi; and (ii) studies must report on outcomes of interest—stroke, bleeding, SE, SSE, mortality, or LV thrombus resolution. No restrictions were placed on the study population. We excluded noncomparative trials, case reports, case series, systematic reviews, and meta-analyses. Abstracts were included, and although authors were contacted for additional data, no unpublished data were obtained. The selection of studies was assessed independently by 2 investigators (F.M., N.N.). Disagreements between authors were resolved through discussion, and when required, consultation with a third author (M.S.).

The quality of the primary studies was assessed in duplicate (by F.M. and N.N.). The Newcastle-Ottawa Scale was used to evaluate cohort studies on selection of study groups, comparability of study groups, and measurement of outcomes. The Cochrane risk-of-bias 2 tool was used to evaluate randomized controlled trials (RCTs) on selection bias, performance bias, detection bias, attrition bias, reporting bias, and other bias. Publication bias was assessed for the primary outcomes of stroke and bleeding (Supplemental Figs. S1 and S2).

Data extraction and outcomes of interest

Two investigators (F.M., N.N.) independently extracted the following data from included studies: study design, sample size, intervention, patient demographics, outcome data, and definitions of outcomes. Disagreements were resolved through discussion, and when necessary, consultation with a third author (M.S.).

The primary outcomes were stroke and bleeding. Secondary outcomes were SE, SSE (composite of stroke and/or systemic embolic events), mortality, and LV thrombus resolution. The definitions of outcomes are summarized in Table 1, for those described in the included studies.

Statistical analysis

The RevMan (version 5) software package provided by the Cochrane Collaboration was used for combining outcomes from the individual studies and for statistical analysis. Outcomes were pooled with the use of a random-effects model as described by DerSimonian and Laird. Summary estimates and 95% confidence intervals (CIs) were reported for dichotomous variables as odds ratios (ORs). The heterogeneity between studies was assessed by means of Cochran χ² and I². An I² > 50% was considered to represent significant heterogeneity. Statistical significance was set as P < 0.05. Comparisons were calculated using the Student t-test. Given the limitations of conducting a meta-analysis with unadjusted event rates, we additionally performed a narrative synthesis of the data.

Results

Literature search and characteristics of included studies

The literature search yielded 3050 studies (937 from PubMed, 1903 from Embase, 205 from CENTRAL, and 5 from other sources, including grey literature, review articles, and reference lists). Duplicates were removed, and we excluded 2637 studies during title and abstract review. The remaining 30 studies were assessed in full text. Eighteen
| Author            | Study design      | VKA, n                               | DOAC, n                             | Etiology of LV thrombus                                                                 | Average follow-up, mos | Outcome definitions                                                                 |
|-------------------|-------------------|--------------------------------------|-------------------------------------|----------------------------------------------------------------------------------------|------------------------|-------------------------------------------------------------------------------------|
| Abdelnabi (2020)  | RCT               | 40 (all warfarin)                    | 39 (all rivaroxaban, 20 mg daily)   | Ischemic cardiomyopathy (78.5%) Idiopathic (20.3%) Peripartum (1.2%)                    | 6                      | **Stroke**: Any type of stroke **SE**: Any type of systemic embolism **Bleeding**: Major bleeding according to ISTH **LV thrombus resolution**: Determined by TTE |
| Alcalai (2020)    | RCT               | 12 (all warfarin)                    | 13 (all apixaban, 5 mg BID)         | Acute MI (100%)                                                                         | 3                      | **Bleeding**: Major bleeding **LV thrombus resolution**: Not defined                  |
| Ali (2020)        | Retrospective cohort | 60 (all warfarin)                  | 32 (rivaroxaban = 18, apixaban = 13, dabigatran = 1) | Ischemic cardiomyopathy (58%) Non-ischemic cardiomyopathy (23%) Acute MI (15%) Takotsubo cardiomyopathy (5%) | 12                     | **LV thrombus resolution**: Determined by TTE **Bleeding**: Major bleeding **Stroke**: Thromboembolic stroke **Bleeding**: GUSTO criteria |
| Alizadeh (2019)   | Prospective cohort | 60 (VKA not specified)             | 38 (rivaroxaban = 22, apixaban = 14, edoxaban = 2) | Acute MI (100%)                                                                         | 21.6                   | **Bleeding**: Major bleeding, including intracranial bleed, major gastrointestinal bleed, and bleed requiring hospital admission **LV thrombus resolution**: Determined by echocardiography or CMR **Stroke**: Clinically documented bleeding **Bleeding**: Minimal, minor and major bleeding according to TIMI **LV thrombus resolution**: Determined by TTE with contrast |
| Bass (2021)       | Retrospective cohort | 769 (all warfarin)                 | 180 (rivaroxaban = 77, apixaban = 79, dabigatran = 29) | Not specified                                                                           | 3                      | **Bleeding**: Major bleeding **LV thrombus resolution**: Determined by TTE with contrast **LV thrombus resolution**: Determined by TTE **Bleeding**: Major bleeding |
| Cochran (2021)    | Retrospective cohort | 59 (all warfarin)                  | 14 (DOAC not specified)            | Acute MI (48%)                                                                          | 12                     | **Bleeding**: Major bleeding **LV thrombus resolution**: Determined by echocardiography **Bleeding**: Major bleeding **LV thrombus resolution**: Determined by echocardiography **Bleeding**: Major bleeding |
| Daher (2020)      | Retrospective cohort | 42 (warfarin = 14,acenocoumarol = 12, warfarin = 12, flunitriol = 16) | 17 (rivaroxaban = 4, apixaban = 12, dabigatran = 1) | Acute MI or ischemic cardiomyopathy (37.3%)                                              | 3                      | **Bleeding**: Major bleeding **LV thrombus resolution**: Determined by TTE with contrast **LV thrombus resolution**: Determined by TTE **Bleeding**: Major bleeding |
| Durrer-Ariyakuddy (2019) | Retrospective cohort | 33 (VKA not specified)            | 20 (DOAC not specified)            | Acute MI (47%) Non-ischemic cardiomyopathy (40%) Ischemic heart disease (13%)            | 20                     | **LV thrombus resolution**: Determined by echocardiography **Bleeding**: Major bleeding **LV thrombus resolution**: Determined by echocardiography **Bleeding**: Major bleeding |
| Gama (2019)       | Retrospective cohort | 53 (all warfarin)                  | 13 (DOAC not specified)            | All patients post-acute MI or heart failure with reduced ejection fraction               | Unknown                | **LV thrombus resolution**: Determined by echocardiography and complemented by CMR when needed |
| Guddeti (2020)    | Retrospective cohort | 80 (all warfarin)                 |                                    |                                                                                         | 12                     |                                                                                      |

*(continued on next page)*
| Author         | Study design       | VKA, n | DOAC, n | Etiology of LV thrombus                  | Average follow-up, mos | Outcome definitions                                                                 |
|---------------|--------------------|--------|---------|-----------------------------------------|------------------------|--------------------------------------------------------------------------------------|
| Iqbal (2020)  | Retrospective cohort| 62     | 22      | 19 (rivaroxaban = 2, apixaban = 15, dabigatran = 2) | 36 ± 17                | Stroke: Confirmed by neuroimaging                                                   |
|               |                    |        |         | Ischemic cardiomyopathy (86.9%)         |                        | Bleeding: Life-threatening bleed requiring hospitalization, reduction in hemoglobin by ≥ 2 g/dL, or bleed requiring endoscopic evaluation |
|               |                    |        |         | Dilated cardiomyopathy (4.76%)         |                        | LV thrombus resolution: Determined by echocardiogram                               |
|               |                    |        |         | Hypertrophic cardiomyopathy (3.57%)   |                        | LV thrombus resolution: Determined by TTE or CMR                                   |
|               |                    |        |         | Myocarditis (2.4%)                      |                        | LV thrombus resolution: Determined by echocardiography                               |
|               |                    |        |         | Unknown (2.4%)                          |                        | LV thrombus resolution: Determined by TTE or CMR                                   |
|               |                    |        |         |                                            |                        | Stroke: Clinically documented stroke                                                |
|               |                    |        |         |                                            |                        | SE: Clinically documented systemic embolism                                        |
|               |                    |        |         |                                            |                        | Bleeding: Event requiring cessation of anticoagulation                               |
|               |                    |        |         |                                            |                        | LV thrombus resolution: Determined by TTE                                          |
| Jaidka (2018) | Retrospective cohort| 37     | 12      | 22 (rivaroxaban 20 mg daily = 13, apixaban 5 mg BID = 8, dabigatran 150 mg BID = 1) | 6                      | LV thrombus resolution: Determined by TTE or CMR                                   |
| Jones (2020)  | Prospective cohort  | 60     | 41      | 41 (rivaroxaban = 24, apixaban = 15, edoxaban = 2) | 26.4 (median)          | LV thrombus resolution: Determined by echocardiography                               |
| Lim (2019)    | Retrospective cohort| 18     | 5       | 5 (rivaroxaban = 2, dabigatran = 3)       | Unknown                | LV thrombus resolution: Determined by echocardiography                               |
| Ratnayake (2020) | Retrospective cohort | 42   | 2       | 2 (all dabigatran)                       | 6                     | LV thrombus resolution: Determined by TTE                                          |
| Robinson (2020)| Retrospective cohort| 236    | 121     | 121 (apixaban, rivaroxaban, and dabigatran) | 12                    | LV thrombus resolution: Determined by TTE                                          |
| Willeford (2020) | Retrospective cohort | 129  | 22      | 22 (rivaroxaban = 18 [15 mg BID followed by 20 mg BID = 11, 20 mg daily = 6, 15 mg daily = 1], apixaban = 4 [2.5 mg BID = 1, 5 mg BID = 3]) | 8.5                   | LV thrombus resolution: Determined by TTE                                          |
| Yunis (2020)  | Retrospective cohort| 200    | 64      | 64 (DOAC not specified)                 | 24                    | LV thrombus resolution: Determined by TTE                                          |

BARC, Bleeding Academic Research Consortium; BID, twice daily dosing; CMR, cardiovascular magnetic resonance imaging; DOAC, direct oral anticoagulant; GUSTO, Global Use of Strategies to Open Occluded Arteries; ISTH, International Society on Thrombosis and Haemostasis; LV, left ventricular; MI, myocardial infarction; RCT, randomized controlled trial; SE, systemic embolism; SSE, stroke or SE; TIMI, thrombolysis in MI; TTE, transthoracic echocardiogram; VKA, vitamin K antagonist.

*DOAC type and doses are provided where specified by the primary study.
studies met inclusion criteria and were included in this meta-analysis. Figure 1 summarizes the literature search and study selection according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards.16 We included 2 RCTs,17,18 2 prospective cohort studies,19,20 and 14 retrospective cohort studies.7-10,17-30 One of the RCTs was limited to data presented at a conference,17 and 7 other studies were abstracts.18,19,21-27,30 The follow-up ranged from 3 months to 36 months. Studies had variable definitions of outcomes, summarized in Table 1. Stroke was reported in 10 studies,7-9,17,18,20-22,29,30 and bleeding in 13 studies.7-10,17-19,20,22,24,26,29,30 The risk of bias assessment was affected by the limited information provided in abstracts. The quality of cohort studies was assessed using the Newcastle-Ottawa Scale, with which a study can be awarded a maximum of 9 points (Table 2).11 Eleven of 18 studies, 6 of which were abstracts, received 6 or fewer points.7,19,21-27,28,30 The quality of RCTs was assessed using the Cochrane risk-of-bias 2 tool (Fig. 2).12 As the 2 RCTs were not available in full text form, they were judged to have some concerns for multiple domains.17,18

Baseline characteristics of patients

The 18 studies included 2666 patients.7,10,17-30 A DOAC (rivaroxaban, apixaban, edoxaban, or dabigatran) was used in 674 patients. A VKA (warfarin, acenocoumarol, or fluidione) was used in 1992 patients. Baseline characteristics of patients included in each primary study are summarized in Supplemental Table S1. Of note, the population was relatively young, with a mean age between 49.1 years and 63.4 years. Additionally, edoxaban was used in only 2 studies.19,20

![Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram of literature search and study selection. LV, left ventricular.](image-url)
| Study                  | Representativeness of the exposed cohort | Selection of the non-exposed cohort | Ascertainment of exposure | Demonstration that outcome of interest was not present at start of study | Comparability of cohorts on the basis of the design or analysis | Assessment of outcome | Length of follow-up sufficient for outcomes to occur | Adequacy of follow-up of cohorts |
|-----------------------|-----------------------------------------|------------------------------------|---------------------------|---------------------------------------------------------------------|-----------------------------------------------------------------|----------------------|------------------------------------------------|----------------------------------|
| Ali (2020)<sup>17</sup> | *                                       | *                                  | *                         | **                                                                  |                                                                  |                      |                                                |                                  |
| Alizadeh (2019)<sup>19</sup> | *                                       | *                                  | *                         | *                                                                   |                                                                  |                      |                                                |                                  |
| Bass (2021)<sup>22</sup> | *                                       | *                                  | *                         | *                                                                   |                                                                  |                      |                                                |                                  |
| Cochran (2021)<sup>7</sup> | *                                       | *                                  | *                         | *                                                                   |                                                                  |                      |                                                |                                  |
| Daher (2020)<sup>32</sup> | *                                       | *                                  | *                         | *                                                                   |                                                                  |                      |                                                |                                  |
| Durrer-Ariyakuddy (2019)<sup>34</sup> | *                                       | *                                  | *                         | *                                                                   |                                                                  |                      |                                                |                                  |
| Gama (2019)<sup>33</sup>  | *                                       | *                                  | *                         | *                                                                   |                                                                  |                      |                                                |                                  |
| Guddeti (2020)<sup>8</sup>   | *                                       | *                                  | *                         | *                                                                   |                                                                  |                      |                                                |                                  |
| Iqbal (2020)<sup>9</sup>    | *                                       | *                                  | *                         | *                                                                   |                                                                  |                      |                                                |                                  |
| Jaidka (2018)<sup>36</sup>  | *                                       | *                                  | *                         | _                                                                   |                                                                  |                      |                                                |                                  |
| Jones (2020)<sup>30</sup>   | *                                       | *                                  | *                         | *                                                                   |                                                                  |                      |                                                |                                  |
| Lim (2019)<sup>37</sup>     | *                                       | *                                  | *                         | _                                                                   |                                                                  |                      |                                                |                                  |
| Ratnayake (2020)<sup>38</sup> | *                                       | *                                  | *                         | _                                                                   |                                                                  |                      |                                                |                                  |
| Robinson (2020)<sup>18</sup> | *                                       | *                                  | *                         | _                                                                   |                                                                  |                      |                                                |                                  |
| Willeford (2020)<sup>29</sup> | *                                       | *                                  | *                         | _                                                                   |                                                                  |                      |                                                |                                  |
| Yunis (2020)<sup>30</sup>   | *                                       | *                                  | *                         | _                                                                   |                                                                  |                      |                                                |                                  |

Asterisks (*) indicate the star rating according to the Newcastle-Ottawa Scale for cohort studies. A study can be awarded a maximum of 4 stars for selection, 2 stars for comparability, and 3 stars for outcome.
Outcomes

**Primary outcomes.** Stroke occurred in 6.0% of patients treated with DOACs and 10.8% of patients treated with VKAs. In comparison to VKAs, there was a statistically significant reduction in stroke among those treated with DOACs (OR 0.63, 95% CI 0.42-0.96; \( P = 0.03; I^2 = 0\% \); Fig. 3). Bleeding occurred in 7.0% of patients on DOACs and 9.7% of patients on VKAs. Although the point estimate favoured DOACs, the difference was not statistically significant (OR 0.72, 95% CI 0.50-1.02; \( P = 0.07; I^2 = 0\% \); Fig. 4).

**Secondary outcomes.** Comparisons of DOACs to VKAs revealed no significant differences in SE (6.7% vs 10.7%; OR 0.77, 95% CI 0.41-1.44; \( P = 0.41; I^2 = 0\% \); Fig. 5), SSE (16.8% vs 22.2%; OR 0.83, 95% CI 0.53-1.33; \( P = 0.45; I^2 = 33\% \); Fig. 6), mortality (12.8% vs 13.3%; OR 1.01, 95% CI 0.64-1.57; \( P = 0.98; I^2 = 0\% \); Fig. 7), or LV thrombus resolution (69.3% vs 69.6%; OR 1.29, 95% CI 0.83-1.99; \( P = 0.26; I^2 = 56\% \); Fig. 8). Primary and secondary outcomes are summarized in Supplemental Table S2.

**Sensitivity analysis**

A sensitivity analysis was conducted for the primary outcomes to explore the impact of excluding abstracts. Stroke remained statistically significant (\( P = 0.03 \)), and the point estimate further favoured DOACs (OR 0.57, 95% CI 0.35-0.95; \( I^2 = 0\% \); Supplemental Fig. S3). Similarly for bleeding, the point estimate further favoured DOACs (OR 0.67, 95% CI 0.45-1.00; \( I^2 = 0\% \)), and the \( P \)-value was reduced to 0.05 (Supplemental Fig. S4).

**Narrative synthesis**

**Primary outcomes.** Ten of the included studies reported on the primary outcome of stroke. Two of these studies were RCTs, \(^7-9,17,18,20-22,29,30\) One of the RCTs reported no stroke in the DOAC and VKA groups, but this study included only 25 participants, and follow-up was limited to 3 months.\(^18\) The second RCT demonstrated significantly fewer strokes over 6 months in those treated with rivaroxaban compared to VKA (0% vs 10%, \( P = 0.04 \)).\(^17\) The remaining 8 cohort studies all demonstrated numerically higher but not statistically significant rates of stroke in the VKA group.\(^7-9,20-22,29,30\)

Bleeding was examined in 13 studies, including 2 RCTs and one prospective cohort study.\(^7-10,17-20,22,24,26,29,30\) Eleven studies reported similar bleeding events in the DOAC and VKA groups.\(^7-10,17,18,22,24,26,29,30\) Two studies, by Alizadeh et al.\(^19\) and Jones et al.,\(^20\) found an increased number of major bleeding events in patients receiving VKAs (\( P = 0.03 \)). Jones et al. found that most of these bleeding events occurred in the context of triple or dual antiplatelet therapy and included

---

**Table 1:**

| Study or Subgroup | DOACs | Control | Weight | OR (95% CI) |
|-------------------|-------|---------|--------|-------------|
| **Events**        | Total | Events  | Total  |             |
| Abdelnabi         | 0     | 39      | 4      | 0.10 [0.01, 1.97] |
| Alcalai           | 0     | 13      | 0      | Not estimable |
| Ali               | 2     | 32      | 9      | 0.38 [0.08, 1.87] |
| Bass              | 14    | 100     | 90     | 0.64 [0.35, 1.15] |
| Cochran           | 14    | 9       | 59     | 0.18 [0.01, 3.34] |
| Guddeti           | 0     | 19      | 2      | 0.81 [0.04, 17.46] |
| Iqbal             | 0     | 22      | 1      | 0.91 [0.04, 23.19] |
| Jones             | 1     | 41      | 3      | 0.47 [0.05, 4.73] |
| Willeford         | 0     | 22      | 7      | 0.36 [0.02, 6.58] |
| Yunis             | 10    | 64      | 34     | 0.90 [0.42, 1.95] |

Total (95% CI) | 446 | 1471 | 100.0% | 0.63 [0.42, 0.96] |

Total events | 27  | 159  |        |             |

Heterogeneity: Tau^2 = 0.00; Chi^2 = 3.72, df = 8 (\( P = 0.88 \)); I^2 = 0%

Test for overall effect: Z = 2.14 (\( P = 0.03 \))
### Figure 4.
Forest plot of the individual and combined rates of bleeding. CI, confidence interval; df, degrees of freedom; DOACs, direct oral anticoagulants; M-H, Mantel-Haenszel.

| Study or Subgroup | DOACs Events | Control Events | Total Events | Total | Weight | Odds Ratio M-H, Random, 95% CI |
|-------------------|--------------|----------------|--------------|-------|--------|--------------------------------|
| Abdelnabi         | 2            | 39             | 40           | 4.6%  | 0.31 [0.06, 1.62]                |
| Alcalai           | 0            | 13             | 2            | 12    | 1.3%  | 0.16 [0.01, 3.60]               |
| Alizadeh          | 0            | 38             | 3            | 60    | 1.4%  | 0.21 [0.01, 4.25]               |
| Bass              | 14           | 180            | 84           | 769   | 36.5% | 0.69 [0.38, 1.24]               |
| Cochran           | 2            | 14             | 8            | 59    | 4.6%  | 1.06 [0.20, 5.66]               |
| Durrer-Ariyakuddy | 0            | 20             | 0            | 33    | Not estimable                    |
| Guddeti           | 1            | 19             | 4            | 80    | 2.5%  | 1.06 [0.11, 10.02]              |
| Iqbal             | 0            | 22             | 6            | 62    | 1.5%  | 0.19 [0.01, 3.57]               |
| Jaidka            | 3            | 12             | 6            | 37    | 5.2%  | 1.72 [0.36, 8.30]               |
| Jones             | 6            | 41             | 19           | 60    | 12.2% | 0.37 [0.13, 1.03]               |
| Robinson           | 8            | 121            | 19           | 236   | 17.4% | 0.81 [0.34, 1.90]               |
| Willeford         | 1            | 22             | 5            | 129   | 2.6%  | 1.18 [0.13, 10.62]              |
| Yunis             | 5            | 64             | 10           | 200   | 10.3% | 1.61 [0.53, 4.90]               |

Total (95% CI): 605 / 1777 / 100.0% | 0.72 [0.50, 1.02]

Heterogeneity: Tau^2 = 0.00; Chi^2 = 8.85, df = 11 (P = 0.64); I^2 = 0%
Test for overall effect: Z = 1.83 (P = 0.07)

### Figure 5.
Forest plot of the individual and combined rates of systemic embolism. CI, confidence interval; df, degrees of freedom; DOACs, direct oral anticoagulants; M-H, Mantel-Haenszel.

| Study or Subgroup | DOACs Events | Control Events | Total Events | Total | Weight | Odds Ratio M-H, Random, 95% CI |
|-------------------|--------------|----------------|--------------|-------|--------|--------------------------------|
| Abdelnabi         | 0            | 39             | 2            | 40    | 4.2%  | 0.19 [0.01, 4.19]               |
| Alcalai           | 0            | 13             | 0            | 12    | Not estimable                    |
| Ali               | 0            | 32             | 5            | 60    | 4.7%  | 0.16 [0.01, 2.90]               |
| Iqbal             | 0            | 22             | 1            | 62    | 3.8%  | 0.91 [0.04, 23.19]              |
| Willeford         | 0            | 22             | 1            | 129   | 3.8%  | 1.90 [0.08, 48.21]              |
| Yunis             | 13           | 64             | 46           | 200   | 83.4% | 0.85 [0.43, 1.71]               |

Total (95% CI): 192 / 503 / 100.0% | 0.77 [0.41, 1.44]

Heterogeneity: Tau^2 = 0.00; Chi^2 = 2.38, df = 4 (P = 0.67); I^2 = 0%
Test for overall effect: Z = 0.83 (P = 0.41)

### Figure 6.
Forest plot of the individual and combined rates of composite stroke or systemic embolism. CI, confidence interval; df, degrees of freedom; DOACs, direct oral anticoagulants; M-H, Mantel-Haenszel.

| Study or Subgroup | DOACs Events | Control Events | Total Events | Total | Weight | Odds Ratio M-H, Random, 95% CI |
|-------------------|--------------|----------------|--------------|-------|--------|--------------------------------|
| Abdelnabi         | 0            | 39             | 2            | 40    | 2.4%  | 0.07 [0.00, 1.24]               |
| Alcalai           | 0            | 13             | 0            | 12    | Not estimable                    |
| Ali               | 2            | 32             | 14           | 60    | 7.1%  | 0.22 [0.05, 1.03]               |
| Bass              | 55           | 180            | 254          | 769   | 29.2% | 0.89 [0.63, 1.27]               |
| Cochran           | 0            | 14             | 9            | 59    | 2.4%  | 0.18 [0.01, 3.34]               |
| Daher             | 2            | 17             | 4            | 42    | 5.6%  | 1.27 [0.21, 7.66]               |
| Guddeti           | 0            | 19             | 2            | 80    | 2.1%  | 0.81 [0.04, 17.46]              |
| Iqbal             | 0            | 22             | 2            | 62    | 2.1%  | 0.54 [0.02, 11.64]              |
| Jaidka            | 0            | 12             | 2            | 37    | 2.1%  | 0.57 [0.03, 12.66]              |
| Jones             | 1            | 41             | 3            | 60    | 3.6%  | 0.47 [0.05, 4.73]               |
| Robinson          | 17           | 121            | 14           | 236   | 18.4% | 2.59 [1.23, 5.46]               |
| Willeford         | 0            | 22             | 8            | 129   | 2.4%  | 0.32 [0.02, 5.70]               |
| Yunis             | 23           | 64             | 80           | 200   | 22.5% | 0.84 [0.47, 1.51]               |

Total (95% CI): 596 / 1786 / 100.0% | 0.83 [0.53, 1.33]

Heterogeneity: Tau^2 = 0.16; Chi^2 = 16.54, df = 11 (P = 0.12); I^2 = 33%
Test for overall effect: Z = 0.76 (P = 0.45)
gastrointestinal bleeding, subarachnoid hemorrhage, and epistaxis requiring hospital admission.

Two studies additionally examined rates of blood product administration. Two studies additionally examined rates of blood product administration. Two studies additionally examined rates of blood product administration. Two studies additionally examined rates of blood product administration.

Secondary outcomes. Six studies looked at the outcome of SE, including 2 preliminary RCTs and 4 retrospective observational studies. In the RCT by Alcalai et al., no patients developed SE in either group after 3 months of follow-up. In all other studies, there was no significant difference in SE between the DOAC and VKA groups, although overall event rates were quite low across the studies.

The composite secondary outcome of SSE was reported in 13 studies. In the multicenter cohort study by Robinson et al., higher hazards of SSE were observed in those treated with DOACs alone (HR 2.88, 95% CI 1.22-6.80; P = 0.02). However, a recently published retrospective cohort study by Bass et al.—the largest to date, with 949 participants—found no difference in SSE between the DOAC and VKA groups (55 of 180 (30.6%) vs 254 of 769 (33%), P = 0.53). Nine other studies also reported no difference in composite SSE events between DOACs and VKAs.

Finally, an RCT by Abdelnabi et al., and a retrospective cohort study by Ali et al., reported significantly fewer composite SSE events with DOACs compared to VKAs (0% vs 15% [P = 0.01] and 6% vs 23% [P = 0.0001], respectively).
significantly greater LV thrombus resolution with DOACs over the entire study period, and 2 other studies found initial resolution to be faster with DOACs, but no significant differences in resolution when measured over the entire study period. Jones et al. reported consistently higher LV thrombus resolution with DOACs compared with VKAs at different time points through the 1-year follow-up period (82% vs 64.4%, \( P = 0.0018 \)) even after adjusting for baseline variables (OR 1.8, 95% CI 1.2-2.9). A similar finding was reported by Alizadeh et al., with LV thrombus resolution greater at 1 year with DOACs compared to VKAs (75% vs 53%, \( P = 0.0018 \)), an effect that persisted with adjustment for baseline variables (OR 1.8, 95% CI 1.2-2.9). 

Finally, 2 studies noted faster thrombus resolution with the use of DOACs at 1 month follow-up, but the overall rates of thrombus resolution were similar between the 2 groups (71.79% vs 47.5%, \( P = 0.03 \) in Abdelnabi et al., and 34% vs 12%, \( P \leq 0.00001 \) in Ali et al.).

Discussion

Our meta-analysis has shown the following: (i) There was a statistically significant decrease in stroke among those treated with DOACs compared to VKAs, without an increase in bleeding; and (ii) there were no significant differences in the secondary outcomes of SE, SSE, mortality, and LV thrombus resolution.

Current guidelines recommend the use of VKAs for treatment of LV thrombi to reduce the risk of stroke and systemic embolism. Given the preference for DOACs in atrial fibrillation, there is considerable interest in using these agents for other indications. DOACs offer numerous benefits over VKAs, including their ease of use, minimal need for monitoring, and fewer drug interactions. When studied in patients with atrial fibrillation, DOACs were associated with decreased SSE and all-cause mortality, with less major bleeding and intracranial hemorrhage compared to VKAs. Unfortunately, these findings have not been established in the LV thrombus population, and the risks and benefits of their use for this indication are unknown.

Primary outcomes

In this meta-analysis, DOAC use was associated with a 37% decrease in odds of stroke compared to VKA use (OR 0.63, 95% CI 0.42-0.96; \( P = 0.03 \), \( I^2 = 0% \)). Ten studies, of which 3 were abstracts or conference proceedings, reported on stroke. None of these studies demonstrated increased stroke events in the VKA group. However, none reached statistical significance, likely owing to small sample size and overall low incidence of stroke during the follow-up period. One study reported no stroke in both the DOAC and VKA groups, but this study included only 25 participants, and follow-up was limited to 3 months. When a sensitivity analysis was performed by excluding the 3 abstracts/conference proceedings, there was still a significant reduction in odds of stroke with DOACs, supporting the original analysis (OR 0.57, 95% CI 0.35-0.95; \( P = 0.03 \), \( I^2 = 0% \)). It is interesting that RCTs comparing DOACs to warfarin in atrial fibrillation have found no significant difference in the risk of ischemic stroke, whereas our meta-analysis suggests a possible reduction in stroke with DOACs. This discrepancy may be attributable to differences in the underlying etiologies of atrial and ventricular thrombi. An LV thrombus is often due to a single insult of an acute MI, as was commonly seen in the included studies (Table 1). This type of thrombus differs from a thrombus due to atrial fibrillation, which is an ongoing process rather than a single event. Therefore, it is possible that the risk of stroke due to an LV thrombus associated with a discrete MI is more easily modifiable than the risk of stroke due to an atrial thrombus, which is associated with an ongoing arrhythmia. Another important factor to consider when interpreting our results is time in therapeutic international normalized ratio (INR). Although these data were not consistently provided across studies, Ali et al. reported that 71% of patients who developed ischemic stroke on warfarin had a subtherapeutic INR. Similarly, Jones et al. found that 35% of patients on VKAs had a subtherapeutic INR. Thus, it is unclear if the higher odds of stroke in those using VKAs are due to issues with compliance, maintenance of therapeutic INR, or inherent differences in the anticoagulants themselves. Previous meta-analyses have not examined stroke as an individual outcome, but rather a composite SSE, making this the first review to demonstrate this statistically significant difference.

However, this finding must be contextualized by the limitations of the primary studies, including the inherent bias of cohort studies and the lack of an adjusted analysis. Further studies—ideally in the form of adequately powered RCTs—are required to substantiate this finding.

Our second primary outcome was bleeding, which was reported in 13 studies in 7 full-text articles, the point estimate for bleeding was further in favour of DOACs (OR 0.67, 95% CI 0.45-1.00; \( P = 0.05 \), \( I^2 = 0% \)). When a sensitivity analysis was performed, including data from only the 7 full-text articles, the point estimate for bleeding was further in favour of DOACs (OR 0.67, 95% CI 0.45-1.00; \( P = 0.05 \), \( I^2 = 0% \)). This finding is consistent with results of 11 of the 13 primary studies, which also found bleeding rates to be similar between the groups. Interpretation of the bleeding data is impacted by the variable definitions of bleeding across studies (Table 1), which affects our ability to draw firm conclusions. First, for example, a number of primary studies focused on major bleeding, such as intracranial hemorrhage or bleeding with hemodynamic instability, whereas other studies measured less-severe bleeding events not requiring hospitalization or transfusion (Table 1). Future research with standardized bleeding definitions will better ascertain bleeding risk. Second, other risk factors for bleeding were not consistently reported across studies, such as concurrent antiplatelet therapy, chronic kidney disease, supratherapeutic INR, and use of high-risk medications, such as steroids and nonsteroidal anti-inflammatory drugs. This consideration is critical, as many of the included patients developed LV thrombi following acute MIs, which typically require concomitant antiplatelet therapy. Iqbal et al. was one of 2 studies to examine bleeding rates among those on antiplatelet therapy, and they reported that half of the patients who had a significant bleed on VKA were receiving dual antiplatelet therapy. Finally, the type and dosage of DOAC prescribed was also inconsistently

...
reported in studies and warrants further investigation. Large RCTs have demonstrated significant differences in bleeding with various DOAC regimens compared to VKAs in the atrial fibrillation population, and it is important to understand whether this relationship also exists in the LV thrombus population.12-13,38

Secondary outcomes

We found no statistically significant differences between DOACs and VKAs across the secondary outcomes of SE, SSE, mortality, and LV thrombus resolution. Six studies reported on SE and did not identify significant differences between those using DOACs vs VKAs (OR 0.77, 95% CI 0.41-1.44; P = 0.41; I² = 0%).10 It is unclear how many of these SE events occurred in the context of a subtherapeutic INR or medication non-adherence, and whether there are differences between individual DOAC agents. No prior meta-analyses examined SE as an individual outcome; hence, SE is an area for future research.

A total of 13 studies measured stroke or SE that were combined into a composite SSE outcome.7,10,17,18,20,22-26,29,30 The cohort study by Robinson et al.—one of the largest conducted on this topic to date (n = 514)—showed significantly more SSE events in the DOAC group (HR 2.88, 95% CI 1.22-6.80; P = 0.02).10 However, a preliminary RCT by Abdelnabi et al. found fewer SSE events in those taking DOACs (0% vs 15%, P = 0.01), as did a retrospective study by Ali et al. (6% vs 23%, P = 0.0001).17,21 The remaining 10 primary studies found no statistically significant difference between DOACs and VKAs.7,9,18,20,22-26,29,30 Similarly, our pooled analysis also showed that DOACs and VKAs were comparable in terms of SSE (OR 0.83, 95% CI 0.53-1.33; P = 0.45; I² = 33%). Concerns about off-label DOAC use in LV thrombus have emerged since the Robinson et al. publication; however, in that study, there were a considerable number of patients who switched treatment groups (n = 52 warfarin to DOAC, n = 19 DOAC to warfarin).10 When data analysis was limited to those who had received only warfarin or only DOACs, the possibility of a four-fold increase in hazards of SSE was identified, but the point estimate was no longer statistically significant (HR 1.99, 95% CI 0.91-4.35; P = 0.08).11 Furthermore, RCT data by Abdelnabi et al. did not support the findings by Robinson et al. instead demonstrating decreased SSE with DOACs. However, this study was also limited by a small sample size and open-label design. Overall, our findings are in keeping with those of other meta-analyses, which have also shown no significant difference in SSE between DOACs and VKAs.

Mortality was reported in 6 of the 18 studies, and no study identified a meaningful difference between DOACs and VKAs.7,9,10,18,24,30 In a meta-analysis by Dalila et al., mortality was found to be 9% higher in patients receiving warfarin compared to those treated with DOACs (risk ratio 1.09, 95% CI 0.70-1.70), but the difference was not statistically significant.46 This finding is in keeping with our results, which showed no significant mortality benefit with use of one anti-coagulant over the other.

There were no significant differences in LV thrombus resolution between those treated with DOACs vs VKAs (OR 1.29, 95% CI 0.83-1.99; P = 0.26; I² = 56%).7-10,17,21-23,30 LV thrombus resolution was assessed at different time points in individual studies, ranging from 3 to 36 months, and this limits interpretation of the results. Although we did not examine time to LV thrombus resolution, Jones et al. identified a greater degree of LV thrombus resolution with DOACs over VKAs at 1 year (81% vs 63%, P = 0.0018), in addition to faster LV thrombus resolution with DOACs.20 Another primary study also reported significantly earlier thrombus resolution with DOACs at 1 month compared to VKAs (34% vs 12%, P ≤ 0.00001).20 Further investigation of the time to thrombus resolution with DOACs vs VKAs, and the association with the risk of SSE, is an avenue for further research. However, an important point to note is that the assessment of LV thrombus resolution varied considerably across studies thereby limiting the conclusions that can be drawn. For example, different imaging modalities were used to assess for thrombus resolution. Most studies used transthoracic echocardiogram, and only 4 used cardiac magnetic resonance imaging,9,19,20,25 which has greater sensitivity in identifying small thrombi.39 Furthermore, only one primary study7 specifically used the contrast, which is known to enhance thrombus detection.40

Strengths

Our meta-analysis has a number of strengths. To the best of our knowledge, this is the largest systematic review and meta-analysis comparing DOACs to VKAs in the management of LV thrombi. Our study pooled data from 18 studies and 2666 participants, making this the most comprehensive review of the literature on this topic to date. Although previous reviews have included data from case reports and observational studies, ours is the first to include data from 2 RCTs.34,36,41 Additionally, previously published meta-analyses have examined fewer outcomes and focused on composite SSE.7-34 In contrast, our meta-analysis examined 6 different safety and efficacy outcomes, and assessed stroke and SE as individual outcomes in addition to the composite SSE that previous reviews have examined. By doing so, we are the first review to identify a statistically significant reduction in stroke with DOAC use.

Limitations

The limitations of our meta-analysis are largely related to the included studies. The majority of primary studies were cohort studies, which are inherently prone to bias, and adjusted events were not consistently reported. Thus, our meta-analysis is limited to the pooling of unadjusted event rates. In addition, of the 18 studies included in this paper, 8 were not full-text articles, and limited information was available to ascertain baseline characteristics of participants and critically appraise study quality.17-19,24-27,30 Although our review includes 2 RCTs, additional data from ongoing larger RCTs will aid in understanding the differences between DOACs and VKAs for this indication.42-44 Also, the length of follow-up and outcome definitions varied considerably across studies (Table 1), which affects the conclusions that can be drawn. Information on important variables was also limited, including the dose of DOAC used, time in therapeutic INR, and concurrent antiplatelet therapy. These factors have
important implications regarding the primary and secondary outcomes studied. The lack of prospective registration was an additional limitation of our study. Lastly, the population studied was relatively young, with a mean age of 49-63 years (Supplemental Table S1). Therefore, the results may not be generalizable to older patients who tend to have higher risks of bleeding and thromboembolic events.

**Conclusion**

Within the context of low-quality evidence, this meta-analysis suggests that DOACs may be an alternative to VKAs in the treatment of LV thrombi. Although a statistically significant reduction in stroke with DOAC use was identified, these results must be interpreted within the limitations of the included studies. Further research through RCTs is required to definitively compare the agents.

**Funding Sources**

Mohammed Shurrab is supported by a Fellowship Award from the Canadian Institutes of Health Research (CIHR).

**Disclosures**

The authors have no conflicts of interest to disclose.

**References**

1. Osherov AB, Borovik-Razi M, Aronson D, et al. Incidence of early left ventricular thrombus after acute anterior wall myocardial infarction in the primary coronary intervention era. Am Heart J 2009;157:1074–80.

2. Solheim S, Seljeflot I, Lunde K, et al. Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy. Am J Cardiol 2010;106:1197–200.

3. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:2160–236.

4. Steg PG, James SK. Task Force on the Management of ST-Elevation Acute Myocardial Infarction of the European Society of Cardiology (ESC), et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569–619.

5. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e362–425.

6. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–62.

7. Cochran JM, Jia X, Kaczmarek J, et al. Direct oral anticoagulants in the treatment of left ventricular thrombus: a retrospective, multicenter study and meta-analysis of existing data. J Cardiovasc Pharmacol Ther 2021;26:173–8.

8. Guddeti R, Anwar M, Walew RW, et al. Treatment of left ventricular thrombus with direct oral anticoagulants: a retrospective observational study. Am J Med 2020;133:1488–91.

9. Iqbal H, Straw S, Craven TP, et al. Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus. ESC Heart Fail 2020;7:2032–41.

10. Robinson AA, Trankle CR, Eubanks G, et al. Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi. JAMA Cardiol 2020;5:685–92.

11. Ottawa Hospital Research Institute. Available at: http://www.ohir.ca/programs/clinical_epidemiology/oxford.asp. Accessed January 17, 2021.

12. Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898.

13. Shurrab M, Danon A, Alnaser S, et al. Dual-antithrombotic therapy with DOACs after acute coronary syndrome or percutaneous coronary intervention in atrial fibrillation: a meta-analysis of randomized controlled trials. Can J Cardiol 2020;36:135–42.

14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.

15. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0.

16. Moher D, Liberati A, Tetzlaff J, Altman DG. Group PRISMA. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264–9.

17. Abdelnabi M, Saleh Y, Fareed A, et al. Comparative study of oral anticoagulation in left ventricular thrombi (No-LVT trial). Available at: https://www.acc.org/clinical-topics/-/media/14EDFF5E70174C-C4995724AB9B68EC.pdf. Accessed February 4, 2021.

18. Alcali R, Rashad R, Butnaru A, Moravsky G, Leibowitz D. Apixaban versus warfarin in patients with left ventricular (LV) thrombus, a prospective randomized trial. Eur Heart J 2020;41:1545.

19. Alizadeh M, Antonius S, Hadil S, et al. The use of direct oral anti-coagulations (DOACs) compared to vitamin K antagonist in patients with left ventricular thrombus after acute myocardial infarction. Eur Heart J 2019;40:4026.

20. Jones D, Wright P, Alizadeh M, et al. The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction (AMI). Eur Heart J Cardiovasc Pharmacother 2020;6:apa096.

21. Ali Z, Isom N, Dalia T, et al. Direct oral anticoagulant use in left ventricular thrombus. Thromb J 2020;18:29.

22. Bass ME, Kiser TH, Page 2nd RL, et al. Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus [e-pub ahead of print]. J Thromb Thrombolysis 2021. https://doi.org/10.1007/s11239-020-02371-6, accessed August 9, 2021.

23. Daher J, Costa A, Hilaire C, et al. Management of left ventricular thrombi with direct oral anticoagulants: retrospective comparative study with vitamin K antagonists. Clin Drug Invest 2020;40:343–53.

24. Durrer-Aryakuddy K, Moccetti F, Stagg SL, et al. Direct oral anticoagulants versus vitamin K-antagonists for treatment of left ventricular thrombus — insights from multicenter registry. Cardiovasc Med 2019;22:w02052.

25. Gama F, Freitas P, Trabulo M, et al. Direct oral anticoagulants are an effective therapy for left ventricular thrombus formation. Eur Heart J 2019;40:166.

26. Jaidka A, Zhu T, Lavi S, Jobri A. Treatment of left ventricular thrombus using warfarin versus direct oral anticoagulants following anterior myocardial infarction. Can J Cardiol 2018;34:S143.

27. Lim CW, Mamat RM, Hishammudin IA. Left ventricular thrombus: patient characteristics and treatment from a single tertiary centre’s experience. Int J Cardiol 2019;297:20–1.
28. Ratnayake C, Liu B, Benatar J, Stewart RAH, Somaratne JB. Left ventricular thrombus after ST segment elevation myocardial infarction: a single-centre observational study. NZ Med J 2020;133:45–54.

29. Willeford A, Zhu W, Stevens C, Thomas IC. Direct oral anticoagulants versus warfarin in the treatment of left ventricular thrombus. Ann Pharmacother 2021;55:839–45.

30. Yunis A, Seese L, Stearns B, et al. Direct oral anticoagulants are effective therapy in treating left ventricular thrombi. J Am Coll Cardiol 2020;75:948.

31. Andrade JG, Aguilar M, Atzema C, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Can J Cardiol 2020;36:1847–948.

32. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–92.

33. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–91.

34. Saleiro C, Lopes J, De Campos D, et al. Left ventricular thrombus therapy with direct oral anticoagulants versus vitamin K antagonists: a systematic review and meta-analysis. J Cardiovasc Pharmacol Ther 2021;26:233–43.

35. Camilli M, Lombardi M, Del Buono M, et al. Direct oral anticoagulants versus vitamin K antagonists for the treatment of left ventricular thrombosis: a systematic review of the literature and meta-analysis. Eur Heart J Cardiovasc Pharmacother 2020:pvaa134.

36. Dalia T, Lahan S, Ranka S, et al. Warfarin versus direct oral anticoagulants for treating left ventricular thrombus: a systematic review and meta-analysis. Thromb J 2021;19:7.

37. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010;138:1093–100.

38. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093–104.

39. Weisnaft JW, Kim HW, Crowley AL, et al. LV thrombus detection by routine echocardiography: Insights into performance characteristics using delayed enhancement CMR. JACC Cardiovasc Imaging 2011;4:702–12.

40. Celeste F, Muratori M, Mapelli M, Pepi M. The evolving role and use of echocardiography in the evaluation of cardiac source of embolism. J Cardiovasc Echogr 2017;27:33–44.

41. Sedhom R, Abdelmaseeh P, Megaly M, Asinger R. Use of direct oral anticoagulants in the treatment of left ventricular thrombi: a systematic review. Am J Med 2020;133:1266–73.

42. Wang L, Meng H. Optimized antithrombotic therapy of acute myocardial infarction with left ventricular mural thrombus (OATH-AMI). Available at: https://clinicaltrials.gov/ct2/show/record/NCT03415386. Accessed February 7, 2021.

43. Pa J, Ge H. Treatment of post-STEMI left ventricular thrombus with optimized anticoagulant (EARLYmyo-LVT). Available at: https://clinicaltrials.gov/ct2/show/record/NCT03764241. Accessed February 7, 2021.

44. Stewart R. A prospective randomized open, blinded end-point controlled study evaluating the resolution and recurrence of left ventricular thrombus with different anti coagulation strategies. Available at: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=375640. Accessed February 7, 2021.

Supplementary Material

To access the supplementary material accompanying this article, visit CJC Open at https://www.cjcopen.ca/ and at doi:10.1016/j.cjco.2021.04.007.